强化监督营养治疗对失代偿期肝硬化肌少症的随机对照试验
这项单中心开放标签随机对照试验纳入180例失代偿期肝硬化合并肌少症患者,比较营养师监督的强化营养治疗与医生主导的指南膳食建议6个月的疗效。结果显示,强化营养治疗在骨骼肌指数、握力和步速改善上均显著优于对照组,多域应答率68.9%对37.8%,但死亡率、住院等临床事件无显著差异。
要点
- 营养师监督的强化营养治疗可显著改善失代偿期肝硬化肌少症患者的骨骼肌质量、握力和步速。
- 强化营养治疗组多域应答率68.9%,对照组37.8%,NNT为3.2。
- 两组在死亡率、住院或其他主要临床事件上无显著差异。
核心结论
- 在失代偿期肝硬化合并肌少症患者中,营养师监督的强化营养治疗在改善骨骼肌质量、力量和躯体功能方面优于医生主导的指南膳食建议。
研究设计与样本
- 单中心、开放标签、随机对照试验,纳入180例失代偿期肝硬化合并肌少症患者,按1:1随机分为营养师监督的强化营养治疗组或医生主导的指南膳食建议组,干预6个月。
主要发现
- 骨骼肌指数组间差异为+2.50 cm2/m2(95%CI 1.30-3.70),握力男性+7.5 kg(95%CI 5.39-9.61)、女性+4.8 kg(95%CI 3.12-6.48),步速+0.23 m/s(95%CI 0.13-0.33),均p<0.001。
- 血清白蛋白组间增加+0.48 g/dL,CTP评分改善-1.30分,MELD评分无变化。
- 多域应答率强化营养治疗组68.9% vs 对照组37.8%(RR 1.82,95%CI 1.36-2.44;NNT 3.2)。
- 营养师监督治疗独立预测SMI应答(OR 3.82;95%CI 1.80-8.10)。
- 死亡率、住院或其他主要临床事件无显著差异。
关键数值与推荐
- 干预组目标能量摄入为35-40 kcal/kg/天,蛋白质摄入为1.2-1.5 g/kg/天,通过结构化营养师监督实施。
临床怎么用
- 对于失代偿期肝硬化合并肌少症患者,可考虑由营养师监督实施强化营养治疗以改善骨骼肌质量、力量和躯体功能。
局限性
- 单中心、开放标签设计可能影响结果的外推性和偏倚控制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sarcopenia is highly prevalent in decompensated cirrhosis and independently predicts adverse outcomes. Although nutritional therapy is guideline-recommended, evidence comparing specialist dietitian-supervised nutritional care with routine physician-delivered dietary advice remains limited. AIM: To compare the efficacy of dietitian-supervised intensive nutritional therapy with physician-led guideline-based dietary advice for improving skeletal muscle mass, strength and physical performance in patients with decompensated cirrhosis and sarcopenia. METHODS: In this single-centre, open-label, randomised controlled trial, 180 patients with decompensated cirrhosis and sarcopenia were randomised (1:1) to dietitian-supervised intensive nutritional therapy or physician-led guideline-based dietary advice for 6 months. The intervention targeted energy intake of 35-40 kcal/kg/day and protein intake of 1.2-1.5 g/kg/day through structured dietitian supervision. The primary outcome was change in skeletal muscle index (SMI); secondary outcomes included handgrip strength (HGS), gait velocity, nutritional status, liver disease severity and clinical outcomes. RESULTS: Dietitian-supervised therapy produced significantly greater improvements than physician-led care in SMI (between-group difference +2.50 cm2/m2; 95% CI 1.30-3.70), HGS (men: +7.5 kg, 95% CI 5.39-9.61; women: +4.8 kg, 95% CI 3.12-6.48) and gait velocity (+0.23 m/s; 95% CI 0.13-0.33) (all p < 0.001). Serum albumin increased (+0.48 g/dL between groups) and CTP score improved (-1.30 points), whereas MELD score remained unchanged. Overall multidomain response occurred in 68.9% versus 37.8% of participants (RR 1.82, 95% CI 1.36-2.44; number needed to treat 3.2). Dietitian-supervised therapy independently predicted SMI response (OR 3.82; 95% CI 1.80-8.10). No significant differences were observed in mortality, hospitalisation or other major clinical events. CONCLUSIONS: In patients with decompensated cirrhosis and sarcopenia, dietitian-supervised intensive nutritional therapy produced greater improvements in skeletal muscle mass, strength and physical performance than routine physician-led guideline-based dietary advice. TRIAL REGISTRATION: CTRI number (www.ctri.nic.in): CTRI/2023/12/060881.
引用
- Dhaked GK, Sharma PN, Sharma KK, et al. Clinical Trial: Intensive Supervised Nutritional Therapy Versus Guideline-Based Nutritional Advice for Sarcopenia in Decompensated Cirrhosis-A Randomised Controlled Trial. Aliment Pharmacol Ther. 2026. PMID: 42643064. doi:10.1111/apt.70938
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。